Semax: The ACTH(4-10) Cognitive Peptide and What the Research Actually Shows

Semax sits in a different corner of the peptide map than BPC-157, GH secretagogues, or GLP-1s. It is a short neuropeptide — seven amino acids — engineered from a fragment of adrenocorticotropic hormone and studied mainly for cognitive and neuroprotective effects. In Russia it has decades of clinical use. In the United States it is not FDA-approved, lives in a compounding gray zone, and is often discussed alongside its cousin Selank as a “Russian nootropic peptide.”

This article walks through what Semax is, how it is thought to work, what human and animal data actually show, and where the evidence is still thin. Educational only — not medical advice, not dosing guidance, not a recommendation to use the compound.

What Semax Is

Semax is the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. It is an analog of ACTH(4-10), the N-terminal fragment of adrenocorticotropic hormone associated with neurotrophic and behavioral effects rather than full adrenal steroidogenesis.

Native ACTH fragments break down quickly. Russian researchers at the Institute of Molecular Genetics extended the sequence with a C-terminal Pro-Gly-Pro motif to slow enzymatic degradation and lengthen activity. That modification is the structural reason Semax can be given intranasally and still produce measurable central effects in animal and human studies.

Importantly, Semax was designed to keep the cognitive/neurotrophic side of ACTH-related signaling while largely dropping the classical hormonal ACTH profile (including MC2R-driven cortisol stimulation). That design intent is why it is discussed as a nootropic and neuroprotectant rather than as a stress-axis hormone.

Mechanism: BDNF, Monoamines, and Plasticity

The most consistent mechanistic story for Semax is upregulation of brain-derived neurotrophic factor (BDNF) and related neurotrophin signaling.

In rat hippocampus, Semax altered BDNF and trkB expression after intranasal administration, with downstream implications for synaptic plasticity and learning (Dolotov et al., Brain Research, 2006). Separate work showed specific binding in basal forebrain regions and increased BDNF protein levels on a shorter time scale after dosing (Dolotov et al., 2006). Other rodent studies report changes in NGF/BDNF gene expression in frontal cortex and hippocampus and modulation of monoaminergic tone, particularly serotonergic systems.

Put simply: Semax appears to nudge neurotrophin pathways and monoamine systems that support attention, learning, and neuronal resilience under stress or injury. That is a plausible biological story. It is not the same thing as large, replicated human outcome trials in healthy aging or dementia — those largely do not exist yet.

What Human Research Shows

Stroke and cerebrovascular disease

The longest clinical trail for Semax is in cerebrovascular disease, mostly from Russian neurology groups.

Early work in acute ischemic stroke reported faster recovery of general and focal neurological deficits when Semax was added to standard care, with supporting EEG and evoked-potential changes (Gusev and colleagues, late 1990s literature). Later clinical series examined courses of intranasal Semax in ischemic stroke and cerebrovascular insufficiency, including associations with plasma BDNF changes and rehabilitation timing, and signals of clinical improvement or fewer exacerbations in chronic cerebrovascular insufficiency cohorts (for example, Gusev et al., 2005, PMID 15792140).

These studies matter because they are human data, not just animal models. They also have real limitations: modest sample sizes by modern stroke-trial standards, often open-label or incompletely blinded designs, Russian-language primary publications, and limited independent Western replication. Treat them as hypothesis-generating clinical experience, not as FDA-grade pivotal evidence.

Healthy volunteers and brain networks

A more modern English-indexed pilot used resting-state fMRI in 24 healthy volunteers. A single intranasal dose of 1% Semax (about 1.2 mg total) increased the volume of the rostral default mode network (DMN) subcomponent — medial frontal cortex territory — at 5 and 20 minutes versus placebo (Lebedeva et al., Bulletin of Experimental Biology and Medicine, 2018).

That is not a memory test score. It is a network-level imaging signal consistent with rapid central activity after nasal delivery. Smaller historical volunteer work (summarized in Russian reviews) has reported short-term improvements in attention and short-term memory with EEG patterns resembling other nootropics. Again: pilot-scale, not definitive cognitive-enhancement proof.

What is missing

There is effectively no high-quality Western RCT program for Semax in mild cognitive impairment, Alzheimer’s disease, ADHD, or healthy longevity. The Alzheimer’s Drug Discovery Foundation’s Cognitive Vitality researcher brief makes this gap explicit: interesting mechanistic and stroke-adjacent signals, very limited English human literature, and no solid clinical case yet for age-related cognitive decline.

If someone is Googling Semax as a longevity or “brain optimization” peptide, honesty requires saying the human evidence is thinner than the internet enthusiasm.

Safety Signals

Available human reports generally describe Semax as well tolerated in short courses. The ADDF brief and Russian clinical summaries commonly list mild, local issues such as nasal cavity discoloration in roughly one in ten users with intranasal administration, and occasional transient blood-glucose increases in some people with diabetes. Serious organ toxicity signals are not a prominent feature of the published short-term literature.

What is not established:

• Long-term safety in healthy adults using research or compounded product
• Drug-interaction profiles in polypharmacy patients
• Immunogenicity and product-quality risks outside pharmaceutical-grade manufacturing
• Safety of non-intranasal routes sometimes discussed in research-chemical markets

As with any unapproved peptide, source quality is part of the risk. A COA is not optional curiosity — see our guide on how to read a peptide COA and the broader sourcing transparency framework.

Regulatory Context (United States)

Semax is not an FDA-approved drug in the U.S. It has been discussed in the same compounding-policy environment as other nominated bulk substances under the 503A framework. Category placement and enforcement posture for individual peptides have shifted over time; anything written here can lag the latest FDA bulk-substance tables.

For clinicians and informed patients, the practical points are:

1. Russian approval is not U.S. approval.
2. Compounded availability is not the same as an FDA finding of safety and efficacy for a labeled indication.
3. The 503A/503B landscape for peptides remains active policy terrain — our 503A/503B landscape overview covers the architecture.

Semax vs Selank (Quick Orientation)

People often pair these two because both are Russian heptapeptides with cognitive/anxiolytic research histories and intranasal use patterns.

They are related by geography and community discourse, not by being interchangeable molecules. If anxiety is the primary question, start with the Selank evidence review. If cognition and neurotrophin signaling are the primary question, Semax is the closer fit.

Practical Takeaways

What the evidence supports reasonably well (with caveats):

• A coherent neurotrophin-centered mechanism in rodent CNS tissue
• Human signals in cerebrovascular/stroke recovery contexts from Russian clinical programs
• Rapid brain-network effects on fMRI after a single intranasal dose in a small healthy-volunteer study
• Generally favorable short-term tolerability in published reports

What the evidence does not yet support to a high standard:

• Large, independently replicated Western RCTs for cognitive enhancement in healthy adults
• Approved use for dementia, ADHD, or anti-aging indications in the United States
• Long-term safety of research-market or compounded products

If you are evaluating any cognitive peptide, start with mechanism literacy (Peptides 101), quality controls (COA guide, sourcing), and clinical context from a licensed professional — not forum protocols. For provider discovery, use the directory. For expert voices in the broader peptide and longevity space, see experts.

Semax is one of the more interesting neuropeptides in the research conversation: real structure-activity design, a BDNF story that is not pure marketing, and human data that is more than zero. It is also a case study in how geography, language barriers, and regulatory status shape what “evidence” looks like online. Read the primary literature, weight study design over hype, and keep medical decisions with clinicians who can evaluate your specific risks.